152 related articles for article (PubMed ID: 25808135)
1. Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).
Li Y; Delamar M; Busca P; Prestat G; Le Corre L; Legeai-Mallet L; Hu R; Zhang R; Barbault F
J Comput Aided Mol Des; 2015 Jul; 29(7):619-41. PubMed ID: 25808135
[TBL] [Abstract][Full Text] [Related]
2. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
3. Discovery of octahydropyrrolo [3,2-b] pyridin derivative as a highly selective Type I inhibitor of FGFR3 over VEGFR2 by high-throughput virtual screening.
Wang X; Ye CH; Li EM; Xu LY; Lin WQ; Chen GH
J Cell Biochem; 2023 Feb; 124(2):221-238. PubMed ID: 36502529
[TBL] [Abstract][Full Text] [Related]
4. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of purin-2-yl and purin-6-yl-aminoglucitols as C-nucleosidic ATP mimics and biological evaluation as FGFR3 inhibitors.
Tak-Tak L; Barbault F; Maurel F; Busca P; Le Merrer Y
Eur J Med Chem; 2011 Apr; 46(4):1254-62. PubMed ID: 21334122
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
7. Role of the N-Terminal Transmembrane Helix Contacts in the Activation of FGFR3.
Matsuoka D; Kamiya M; Sato T; Sugita Y
J Comput Chem; 2020 Mar; 41(6):561-572. PubMed ID: 31804721
[TBL] [Abstract][Full Text] [Related]
8. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
[TBL] [Abstract][Full Text] [Related]
9. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
10. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3.
Volynsky PE; Polyansky AA; Fakhrutdinova GN; Bocharov EV; Efremov RG
J Am Chem Soc; 2013 Jun; 135(22):8105-8. PubMed ID: 23679838
[TBL] [Abstract][Full Text] [Related]
11. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
12. FGFR3 targeting strategies for achondroplasia.
Laederich MB; Horton WA
Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
14. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
15. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
Sarabipour S; Hristova K
Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
[TBL] [Abstract][Full Text] [Related]
16. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma.
Ke K; Li H; Yao H; Shi XN; Dong C; Zhu Y; Liu X; Li L; Leung KS; Wong MH; Liu XD; Kung HF; Lin MC
Chem Biol Drug Des; 2017 Apr; 89(4):505-513. PubMed ID: 27664399
[TBL] [Abstract][Full Text] [Related]
17. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
[TBL] [Abstract][Full Text] [Related]
19. NMR backbone assignments of the tyrosine kinase domain of human fibroblast growth factor receptor 3 in apo state and in complex with inhibitor PD173074.
Sanfelice D; Koss H; Bunney TD; Thompson GS; Farrell B; Katan M; Breeze AL
Biomol NMR Assign; 2018 Oct; 12(2):231-235. PubMed ID: 29582384
[TBL] [Abstract][Full Text] [Related]
20. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
